European Medicines Agency recommends granting a conditional marketing authorisation in the EU for idecabtagene vicleucel (Abecma) for the treatment of relapsed and refractory multiple myeloma
The recommendation is for its use in adults who have received ≥3 previous therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment.
Source:
European Medicines Agency